178 related articles for article (PubMed ID: 29151068)
1. Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences.
Zorniak M; Szydlo B; Krzeminski TF
J Physiol Pharmacol; 2017 Aug; 68(4):521-526. PubMed ID: 29151068
[TBL] [Abstract][Full Text] [Related]
2. Hawthorn revisited: time- and dose-dependent cardioprotective action of WS-1442 special extract in the reperfusion-induced arrhythmia model in rats in vivo.
Zorniak M; Porc MP; Krzeminski TF
J Physiol Pharmacol; 2019 Apr; 70(2):. PubMed ID: 31443093
[TBL] [Abstract][Full Text] [Related]
3. [In vitro and in vivo studies on the cardioprotective action of oligomeric procyanidins in a Crataegus extract of leaves and blooms].
Chatterjee SS; Koch E; Jaggy H; Krzeminski T
Arzneimittelforschung; 1997 Jul; 47(7):821-5. PubMed ID: 9324931
[TBL] [Abstract][Full Text] [Related]
4. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without Hawthorn special extract WS 1442.
Habs M
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():36-9. PubMed ID: 15353901
[TBL] [Abstract][Full Text] [Related]
5. Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion.
Veveris M; Koch E; Chatterjee SS
Life Sci; 2004 Feb; 74(15):1945-55. PubMed ID: 14761675
[TBL] [Abstract][Full Text] [Related]
6. Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177.
Brixius K; Willms S; Napp A; Tossios P; Ladage D; Bloch W; Mehlhorn U; Schwinger RH
Cardiovasc Drugs Ther; 2006 Jun; 20(3):177-84. PubMed ID: 16779533
[TBL] [Abstract][Full Text] [Related]
7. Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review.
Holubarsch CJF; Colucci WS; Eha J
Am J Cardiovasc Drugs; 2018 Feb; 18(1):25-36. PubMed ID: 29080984
[TBL] [Abstract][Full Text] [Related]
8. A novel approach to prevent endothelial hyperpermeability: the Crataegus extract WS® 1442 targets the cAMP/Rap1 pathway.
Bubik MF; Willer EA; Bihari P; Jürgenliemk G; Ammer H; Krombach F; Zahler S; Vollmar AM; Fürst R
J Mol Cell Cardiol; 2012 Jan; 52(1):196-205. PubMed ID: 22085704
[TBL] [Abstract][Full Text] [Related]
9. Crataegus Special Extract WS 1442 Effects on eNOS and microRNA 155.
Wang X; Liang Y; Shi J; Zhu HJ; Bleske BE
Planta Med; 2018 Oct; 84(15):1094-1100. PubMed ID: 29660753
[TBL] [Abstract][Full Text] [Related]
10. Crataegus special extract WS 1442 causes endothelium-dependent relaxation via a redox-sensitive Src- and Akt-dependent activation of endothelial NO synthase but not via activation of estrogen receptors.
Anselm E; Socorro VF; Dal-Ros S; Schott C; Bronner C; Schini-Kerth VB
J Cardiovasc Pharmacol; 2009 Mar; 53(3):253-60. PubMed ID: 19247189
[TBL] [Abstract][Full Text] [Related]
11. The Dual Edema-Preventing Molecular Mechanism of the Crataegus Extract WS 1442 Can Be Assigned to Distinct Phytochemical Fractions.
Fuchs S; Bischoff I; Willer EA; Bräutigam J; Bubik MF; Erdelmeier CAJ; Koch E; Faleschini MT; De Mieri M; Bauhart M; Zahler S; Hensel A; Hamburger M; Potterat O; Fürst R
Planta Med; 2017 May; 83(8):701-709. PubMed ID: 28006832
[TBL] [Abstract][Full Text] [Related]
12. Health effects of hawthorn.
Dahmer S; Scott E
Am Fam Physician; 2010 Feb; 81(4):465-8. PubMed ID: 20148500
[TBL] [Abstract][Full Text] [Related]
13. Hawthorn special extract WS® 1442 increases red blood cell NO-formation without altering red blood cell deformability.
Rieckeheer E; Schwinger RH; Bloch W; Brixius K
Phytomedicine; 2011 Dec; 19(1):20-4. PubMed ID: 21899992
[TBL] [Abstract][Full Text] [Related]
14. Adverse-event profile of Crataegus spp.: a systematic review.
Daniele C; Mazzanti G; Pittler MH; Ernst E
Drug Saf; 2006; 29(6):523-35. PubMed ID: 16752934
[TBL] [Abstract][Full Text] [Related]
15. Standardized extracts from hawthorn leaves and flowers in the treatment of cardiovascular disorders--preclinical and clinical studies.
Koch E; Malek FA
Planta Med; 2011 Jul; 77(11):1123-8. PubMed ID: 21384315
[TBL] [Abstract][Full Text] [Related]
16. [Crataegus oxyacantha (aubepine) in the use as herb medicine in France].
Ju LY
Zhongguo Zhong Yao Za Zhi; 2005 Apr; 30(8):634-40. PubMed ID: 16011292
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the content and stability of the constituents of mother tinctures and tinctures: the case of Crataegus oxyacantha L. and Hieracium pilosella L.
Bilia AR; Eterno F; Bergonzi MC; Mazzi G; Vincieri FF
J Pharm Biomed Anal; 2007 May; 44(1):70-8. PubMed ID: 17331690
[TBL] [Abstract][Full Text] [Related]
18. Composition and health effects of phenolic compounds in hawthorn (Crataegus spp.) of different origins.
Yang B; Liu P
J Sci Food Agric; 2012 Jun; 92(8):1578-90. PubMed ID: 22488722
[TBL] [Abstract][Full Text] [Related]
19. SAFETY AND EFFECTS OF
Niederseer D; Ledl-Kurkowski E; Kvita K; Funk P; Niebauer J
Acta Clin Croat; 2019 Dec; 58(4):604-614. PubMed ID: 32595244
[TBL] [Abstract][Full Text] [Related]
20. Towards a systematic scientific approach in the assessment of efficacy of an herbal preparation: Hawthorn (Crataegus spp.).
Furey A; Tassell M
Eur J Heart Fail; 2008 Dec; 10(12):1153-7. PubMed ID: 18996738
[No Abstract] [Full Text] [Related]
[Next] [New Search]
